Proteinuria and favourable clinical response in a patient receiving paclitaxel + bevacizumab for metastatic breast cancer

Ann Oncol. 2010 Aug;21(8):1729-1730. doi: 10.1093/annonc/mdq328. Epub 2010 Jul 1.

Authors

N Karachaliou¹, E Saloustros¹, L Vamvakas¹, D Mavroudis¹, V Georgoulias²

Affiliations

¹ Department of Medical Oncology, University General Hospital of Heraklion, Heraklion, Crete, Greece.
² Department of Medical Oncology, University General Hospital of Heraklion, Heraklion, Crete, Greece. Electronic address: georgsec@med.uoc.gr.

PMID: 20601370
DOI: 10.1093/annonc/mdq328

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Angiogenesis Inhibitors / administration & dosage
Angiogenesis Inhibitors / therapeutic use*
Antibodies, Monoclonal / administration & dosage
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Phytogenic / administration & dosage
Antineoplastic Agents, Phytogenic / therapeutic use*
Bevacizumab
Breast Neoplasms / drug therapy*
Breast Neoplasms / pathology
Carcinoma, Ductal, Breast / drug therapy*
Carcinoma, Ductal, Breast / pathology
Female
Humans
Neoplasm Metastasis
Paclitaxel / administration & dosage
Paclitaxel / therapeutic use*
Proteinuria / chemically induced*
Treatment Outcome

Substances

Angiogenesis Inhibitors
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Phytogenic
Bevacizumab
Paclitaxel